OncoArendi Therapeutics Reports Continued Strategic and Operational Momentum for 12 Months ended 31 December 2021 Mar 25, 2022 04:00AM
OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan Mar 11, 2022 12:21PM
OncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr. Zbigniew Zasłona and Agnieszka Rajczuk-Szczepańska to its Management Board Jan 31, 2022 07:52AM
OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer Jan 27, 2022 06:53AM
OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members Jan 14, 2022 02:00AM